IP Library › Granted Patent US 12,390,456
Granted Patent B2
US 12,390,456 · App. 17/352,305 · Granted Aug 19, 2025

Pridopidine for treating Huntington's disease

Inventors: Merav Bassan (Netanya, IL); Esther Lukasiewicz Hagai (Tel Aviv, IL); Eli Eyal (Petah-Tikva, IL); Anna Kristina Sveinsdotter Teige Wickenberg (Lund, SE)
Assignee: Prilenia Neurotherapeutics Ltd.
A61K31/451A61K9/0053A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,456
App. No.
17/352,305
Granted
Aug 19, 2025
Kind
B2
Abstract

A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.

Claims (9)

1. A method of reducing impairment of functional capacity of a human patient afflicted with Huntington's disease, consisting essentially of orally administering to the human patient a pharmaceutical composition comprising only pridopidine or a pharmaceutically acceptable salt thereof as the active ingredient, thereby reducing impairment of functional capacity of the human patient.

2. The method of claim 1 , wherein the human patient has ≥36 CAG repeats in the Huntingtin gene.

3. The method of claim 1 , wherein the pharmaceutical composition is administered twice per day.

4. The method of claim 3 , wherein an equal amount of the pharmaceutical composition is administered at each administration.

5. The method of claim 1 , wherein the impairment of the human patient's functional capacity is measured by the Unified Huntingtin's Disease Rating Scale (UHDRS) Total Functional Capacity (TFC).

6. The method of claim 1 , wherein the pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof is administered at a dose of between 90 mg and 225 mg per day.

7. The method of claim 1 , wherein the pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof is administered at a dose of between 90 mg and 180 mg per day.

8. The method of claim 7 , wherein the pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof is administered at a dose of 90 mg b.i.d. per day.

9. The method of claim 7 , wherein the pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof is administered at a dose of 45 mg b.i.d. per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2021
From: BASSAN, MERAV; HAGAI, ESTHER LUKASIEWICZ; EYAL, ELI; SVEINSDOTTER TEIGE WICKENBERG, ANNA KRISTINA
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 056645/0701 →
Continuity (5)
Continuation 16438508 · Jun 12, 2019
Continuation In Part 14309111 · Jun 19, 2014
Provisional Application 61877832 · Sep 13, 2013
Provisional Application 61837928 · Jun 21, 2013
Related Publication 20210308115A1 · Oct 7, 2021
References Cited (171)
US 6903120B2 · Sonesson et al. · 2005 [cited by applicant]
US 7417043B2 · Sonesson et al. · 2008 [cited by applicant]
US 7923459B2 · Gauthier et al. · 2011 [cited by applicant]
US 8669048B2 · Reijo Pera et al. · 2014 [cited by applicant]
US 8703763B2 · Baumann et al. · 2014 [cited by applicant]
US 8703764B2 · Sheldon · 2014 [cited by applicant]
US 9006445B2 · Sonesson et al. · 2015 [cited by applicant]
US 9012476B2 · Zimmermann et al. · 2015 [cited by applicant]
US 9139525B2 · Wikström · 2015 [cited by applicant]
US 9187567B2 · Nichols et al. · 2015 [cited by applicant]
US RE46117E · Sonesson et al. · 2016 [cited by applicant]
US 9602765B2 · Wang et al. · 2017 [cited by applicant]
US 9744155B2 · Matson · 2017 [cited by applicant]
US 9796673B2 · Wu et al. · 2017 [cited by applicant]
US 9814706B2 · Zimmermann et al. · 2017 [cited by applicant]
US 10047049B2 · Barel et al. · 2018 [cited by applicant]
US 10130621B2 · Schmidt et al. · 2018 [cited by applicant]
US 20100048509A1 · Kovacic et al. · 2010 [cited by applicant]
US 20110206782A1 · Zhang · 2011 [cited by applicant]
US 20130150406A1 · Anne et al. · 2013 [cited by applicant]
US 20130197031A1 · Sonesson · 2013 [cited by applicant]
US 20130267552A1 · Waters et al. · 2013 [cited by applicant]
US 20140088140A1 · Hayden et al. · 2014 [cited by applicant]
US 20140088145A1 · Hayden et al. · 2014 [cited by applicant]
US 20140378508A1 · Bassan et al. · 2014 [cited by applicant]
US 20150202302A1 · Licht et al. · 2015 [cited by applicant]
US 20150209346A1 · Hayden · 2015 [cited by applicant]
US 20150216850A1 · Hayden et al. · 2015 [cited by applicant]
US 20150374677A1 · Schmidt · 2015 [cited by examiner]
US 20160095847A1 · Sonesson · 2016 [cited by applicant]
US 20160166559A1 · Sonesson · 2016 [cited by applicant]
US 20160243098A1 · Geva et al. · 2016 [cited by applicant]
US 20170020854A1 · Licht et al. · 2017 [cited by applicant]
US 20170022158A1 · Barel et al. · 2017 [cited by applicant]
US 20170266170A1 · Waters et al. · 2017 [cited by applicant]
US 20180055832A1 · Hayden et al. · 2018 [cited by applicant]
US 20180235950A1 · Sonesson · 2018 [cited by applicant]
US 20190015401A1 · Sonesson · 2019 [cited by applicant]
US 20190030016A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190046516A1 · Russ et al. · 2019 [cited by applicant]
US 20190192496A1 · Hayden et al. · 2019 [cited by applicant]
US 20190209542A1 · Licht et al. · 2019 [cited by applicant]
US 20190231768A1 · Geva · 2019 [cited by examiner]
WO WO2001046145 · 2001 [cited by applicant]
WO WO2005097122 · 2005 [cited by applicant]
WO WO2006040155 · 2006 [cited by applicant]
WO WO2007067617 · 2007 [cited by applicant]
WO WO2008127188 · 2008 [cited by applicant]
WO WO2011107583 · 2011 [cited by applicant]
WO WO2012028635 · 2012 [cited by applicant]
WO WO2013034622 · 2013 [cited by applicant]
WO WO2013086425 · 2013 [cited by applicant]
WO WO2013152105 · 2013 [cited by applicant]
WO WO2015112601 · 2015 [cited by applicant]
WO WO2016003919 · 2016 [cited by applicant]
WO WO2016138130 · 2016 [cited by applicant]
WO WO2016138135 · 2016 [cited by applicant]
WO WO2017015609 · 2017 [cited by applicant]
WO WO2017015615 · 2017 [cited by applicant]
WO WO2017048457 · 2017 [cited by applicant]
WO WO2017147366 · 2017 [cited by applicant]
WO WO2018039475 · 2018 [cited by applicant]
WO WO2018039477 · 2018 [cited by applicant]
WO WO2018053275 · 2018 [cited by applicant]
WO WO2018053280 · 2018 [cited by applicant]
WO WO2018053287 · 2018 [cited by applicant]
WO WO2018136600 · 2018 [cited by applicant]
WO WO2019036358 · 2019 [cited by applicant]
WO WO2019046568 · 2019 [cited by applicant]
WO WO2019050775 · 2019 [cited by applicant]
Lundin, A., et al. (2010). Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease. Clinical neuropharmacology, 33(5), 260- 264. [cited by applicant]
Squitieri, F., et al. (2013). One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology, 80(12), 1086-1094. [cited by applicant]
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual review of neuroscience, 9(1), 357-381. [cited by applicant]
Bechtel, N. et al. (2010)-Tapping linked to function and structure in premanifest and symptomatic Huntington disease—Neurology, 75(24), 2150-2160. [cited by applicant]
Bemelmans, Alexis-Pierre, et al. (1999). Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Human … [cited by applicant]
Bezdicek, O., et al. (2013). Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Applied Neuropsychology: Adult, 20(1), 33-40. [cited by applicant]
Bowie, C. R., & Harvey, P. D. (2006). Administration and interpretation of the Trail Making Test. Nature protocols, 1(5), 2277. [cited by applicant]
Briefs, B., 2010, NeuroSearch's dopaminergic stabilizer improves movement disorders in Huntington's disease. Nature Reviews Drug Discovery 9, 260. [cited by applicant]
Brown, M., Sinacore, D. R., Binder, E. F., & Kohrt, W. M. (2000). Physical and performance measures for the identification of mild to moderate frailty. The Journals of Gerontology Series A: Biological Sciences and Medic… [cited by applicant]
Canals, Josep M., et al. (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. Journal of Neurosci… [cited by applicant]
Carlsson Research; May 8, 2006; “Carlsson Research Reports Positive Effects of ACR16 in Huntington Disease Phase II Study” Press Release. [cited by applicant]
Carlsson, A., & Lindqvist, M. (1963). Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta pharmacologica et toxicologica, 20(2), 140-144. [cited by applicant]
Cepeda, C., Cummings, D. M., André, V. M., Holley, S. M., & Levine, M. S. (2010). Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN neuro, 2(2), AN20090058. [cited by applicant]
Cho, Sung-Rae, et al. (2007) .Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. The Journal of clinical investigation, 117.10: 2889-2902. [cited by applicant]
Ciammola, A., et al. 2007. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 144.4: 574-577. [cited by applicant]
Clinical Trial EudraCT Number 2004-000394-60, “A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease” EU … [cited by applicant]
Clinical Trial, NCT00665223, “A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease (MermaiHD)”, ClinicalTrials.gov, Sponsor Teva Pharmaceutical Industries, First Posted: Apr. 23, 2008 http… [cited by applicant]
Clinical Trial, NCT00724048, “A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease (HART)”, ClinicalTrials.gov, Sponsor Teva Pharmaceutical Industries, First Posted: Jul. 29, 2008 https… [cited by applicant]
Constantinescu et al. (Mar. 2009)—Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease, Parkinsonism & Related Disorders, p. 245-248. [cited by applicant]
Craufurd, D., Thompson, J. C., & Snowden, J. S. (2001). Behavioral changes in Huntington disease. Cognitive and Behavioral Neurology, 14(4), 219-226. [cited by applicant]
Dahlen, Patrik; NeuroSearch A/S reports conclusions from the Multiple Ascending Dose study (MAD) with Huntexil®, May 28, 2012. [cited by applicant]
De Yebenes, J. G., et al. (2011). Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 10… [cited by applicant]
Dragatsis, Ioannis; Levine, Michael S.; Zeitlin, Scott. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature genetics, 2000, 26.3: 300-306. [cited by applicant]
Dubinsky, R., et al. (2010). Third Annual Huntington Disease Clinical Research Symposium. Neurotherapeutics, 7(1), 135-147. [cited by applicant]
Dunlop, B. W., & Nemeroff, C. B. (2007). The role of dopamine in the pathophysiology of depression. Archives of general psychiatry, 64(3), 327-337. [cited by applicant]
Dyhring, T., et al. (2010). The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. European journal of pharmacology, 628(1-3),… [cited by applicant]
Exploratory Population Pharmacokinetic Modeling and Simulations With Pridopidine (Report No. CP-13-013), Jul. 10, 2013, Pharsight Consulting Services. [cited by applicant]
Extended European Search Report for EP Application No. 1481362.1 dated Jan. 11, 2017. [cited by applicant]
Ferrara, J. M. et al.(2012)-Effect of tetrabenazine on motor function in patients with Huntington disease—Neurology and therapy, 1(1), 5. [cited by applicant]
Ferrer, I., et al. Brain-derived neurotrophic factor in Huntington disease. Brain research, 2000, 866.1-2: 257-261. [cited by applicant]
Francardo, Veronica, et al. Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of parkinson's disease. Neurotherapeutics, 2019, 16.2: 465-479. [cited by applicant]
Gauthier, Laurent R., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 2004, 118.1: 127-138. [cited by applicant]
Geva, M., et al. Pridopidine for the Treatment of Early Huntington's Disease: 250. Movement Disorders, 2020, 35. [cited by applicant]
Geva, Michal, et al. (2016) Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Human molecular genetics, 25.18: 3975-3987. [cited by applicant]
Gharami, Kusumika, et al. (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. Journal of neurochemistry, 105.2: 369-379. [cited by applicant]
Giralt, A., et al. (2009). Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCγ activity and glutamate receptor expression. Neuro… [cited by applicant]
Group, T. E. (1990). EuroQol-a new facility for the measurement of health-related quality of life. Health policy, 16(3), 199-208. [cited by applicant]
Guy, W. E. (1976). ECDEU assessment manual for psychopharmacology-revised (DHEW Publ No. ADM 76-338). Rockville, MD, US Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Menta… [cited by applicant]
Hedlin, M.(2011)—Pridopidine-Huntexil-ACR-16-Hopes-Huntington's Disease Information—XP055707622—Retrieved from the Internet—URL:https://hopes.stanford.edu/pridopidine-huntexil-acr-16/. [cited by applicant]
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. [cited by applicant]
Hocaoglu, M. B., Gaffan, E. A., & Ho, A. K. (2012). The Huntington's Disease health-related Quality of Life questionnaire (HDQoL): a disease-specific measure of health-related quality of life. Clinical genetics, 81(2), … [cited by applicant]
Huang, Y. C., et al. (2011). Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. PLoS One, 6(1), p. 1-9. [cited by applicant]
Huntington Study Group HART Investigators. (2013). A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Movement Disorders, 28(10), 1407-1415. [cited by applicant]
Huntington Study Group Trend-HD Investigators. (2008). Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease. Archives of neurology, 65(12), 1582-1589. [cited by applicant]
Huntington Study Group. (2003). Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology, 61(11), 1551-1556. [cited by applicant]
Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology, 66(3), 366-372. [cited by applicant]
Huntington, H. S. G. (1996). Unified Huntington's disease rating scale: reliability and consistency. Movement Disorders, 11, 136-142. [cited by applicant]
Huot, P., Lévesque, M., & Parent, A. (2006). The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain, 130(1), 222-232. [cited by applicant]
International Search Report and Written Opinion for PCT application No. PCT/US2014/043204 dated Oct. 10, 2014. [cited by applicant]
International Search Report and Written Opinion for PCT application No. PCT/US2017/048461 dated Aug. 24, 2017. [cited by applicant]
International Search Report for PCT Application No. PCT/IL2020/050654 dated Aug. 4, 2020. [cited by applicant]
Joffres, C., Graham, J., & Rockwood, K. (2000). Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. International psychogeriat… [cited by applicant]
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008). NMDA receptors in clinicalneurology: excitatory times ahead. The Lancet Neurology, 7(8), 742-755. [cited by applicant]
Kingma, E. M., van Duijn, E., Timman, R., van der Mast, R. C., & Roos, R. A. (2008). Behavioural problems in Huntington's disease using the Problem Behaviours Assessment. General hospital psychiatry, 30(2), 155-161. [cited by applicant]
Kung, V. W. S., Hassam, R., Morton, A. J., & Jones, S. (2007). Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience, 146(4), 1571-1580. [cited by applicant]
Landwehrmeyer, B., Marder, K., Rønn, B., & Haglund, M. (2011). Effects of the Dopaminergic Stabilizer Pridopidine on Motor Symptoms in Huntington's Disease: a Meta-Analysis: 211. Clinical Genetics, 80, 48-49. [cited by applicant]
Mahant, N., McCusker, E. A., Byth, K., Graham, S., & Huntington Study Group. (2003). Huntington's disease: clinical correlates of disability and progression. Neurology, 61(8), 1085-1092. [cited by applicant]
Mangiarini, Laura, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 1996, 87.3: 493-506. [cited by applicant]
McGarry, A., et al. (2017). Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (Hd): A Comparison of Open-HART Subjects with Historical Placebo Controls (p. 2. 011). [cited by applicant]
Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., & Sampaio, C. (2009). Therapeutic interventions for disease progression in Huntington's disease. Cochrane database of systematic reviews, (3). [cited by applicant]
Michl, M., Schnopfhagen, K., & Bonelli, R. M. (2013). Pridopidine in the pharmacological treatment of Huntington's disease. Clinical Investigation, 3(7), 691-699. [cited by applicant]
Millter, Marsha, 2006, “Swedish Company Announces Results of Phase II study of Dopamine Stabilizing Compound” Huntington's Disease Advocacy Center, http://www.hdac.org/features/article.php?p articleNumber=254. [cited by applicant]
Myers, R. H., et al. (1991). Factors associated with slow progression in Huntington's disease. Archives of neurology, 48(8), 800-804. [cited by applicant]
Natesan, S., et al. (2006). The dopamine stabilizers (S)-(−)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(−)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupan… [cited by applicant]
NeuroSearch and Fleming Pederson, Feb. 3, 2010, “NeuroSearch announces positive top-line results from Phase III Huntexil® study in Huntington's disease (the MermaiHD study)”. [cited by applicant]
NeuroSearch and Patrik Dahlen, Sep. 27, 2011, “NeuroSearch provides update on the Huntexil® development programme and plans a comprehensive restructuring of the company's operations”. [cited by applicant]
Neurosearch, May 28, 2012, “NeuroSearch A/S reports conclusions from the Multiple Ascending Dose study (MAD) with Huntexil®”. [cited by applicant]
NewsHD, “Sorry folks, the Pride-HD trial did Not show that Pridopidine slows the progression of Huntington's disease,” Oct. 1, 2016, http://www.newshd.net/hdbuzz/9617/sorry-folks-the-pride-hd-trial-did-not-show-that-pri… [cited by applicant]
NewsHD, “Teva Announces Results from Exploratory 52-Week Phase 2 Pride-HD Study of Pridopidine in Huntington Disease,” Sep. 19, 2016, http://www.newshd.net/important/9571/teva-announces-results-from-exploratory-52-week-… [cited by applicant]
Nieoullon, A., & Coquerel, A. (2003). Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Current Opinion in Neurology, 16, S3-S9. [cited by applicant]
Osterberg, O et al. (2012) “A single-center, randomized, placebo-controlled, doubleblind study to evaluate the safety” Presented at the Sixth Annual Huntington Disease Clinical Research Symposium, Neurotherapeutics, 9(1… [cited by applicant]
Osterberg, O et al. (2013) “A single-center, randomized, placebo-controlled, doubleblind study to evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of pridopidine in healthy volunteers”… [cited by applicant]
Paulsen, J. S., Wang et al. (2010)—Challenges assessing clinical endpoints in early Huntington disease. Movement Disorders, 25(15), pp. 2595-2603. [cited by applicant]
Peng, Qi, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Experimental neurology, 2008, 210.1: 154-163. [cited by applicant]
PÉrez-Navarro, Esther, et al. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. Journal of neurochemistry… [cited by applicant]
Pineda, José R., et al. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. Journal of neurochemistry, 2005, 93.5: 1057-1068. [cited by applicant]
Podsiadlo, D., & Richardson, S. (1991). The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. Journal of the American geriatrics Society, 39(2), 142-148. [cited by applicant]
Ponten, H., et al. (2010). In vivo pharmacology of the dopaminergic stabilizer pridopidine. European journal of pharmacology, 644(1-3), 88-95. [cited by applicant]
Posner, K.,et al. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. American journal of psychiatry, 168(12),… [cited by applicant]
Raffelsbauer, Diane, EHDN News, Article of the Month, Jan. 2012, Issue 15. [cited by applicant]
Rao, A. K., Muratori, L., Louis, E. D., Moskowitz, C. B., & Marder, K. S. (2009). Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness. Gait & posture, 29(3), 433… [cited by applicant]
Reuben, D. B., & Siu, A. L. (1990). An objective measure of physical function of elderly outpatients: the Physical Performance Test. Journal of the American Geriatrics Society, 38(10), 1105-1112. [cited by applicant]
Simmons, Danielle A., et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proceedings of the National Academy of Sciences, 2009, 106.12: 4906-4911. [cited by applicant]
Slow, Elizabeth J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human molecular genetics, 2003, 12.13: 1555-1567. [cited by applicant]
Spires, Tara L., et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. Journal of Neuroscience, 2004, 24.9: 2270-2276. [cited by applicant]
Squitieri, F. et al. (2015). Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug design, development and therapy, 9, 5827. [cited by applicant]
Squitieri, Ferdinando, et al. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Journal of cellular and molecular medicine, 2015, 19… [cited by applicant]
Strand, Andrew D., et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. Journal of Neuroscience, 2007, 27.43: … [cited by applicant]
Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of experimental psychology, 18(6), 643. [cited by applicant]
Waters, S, et al., (2009), Medical Treatments. Pharmacology of the dopaminergic stabilizer pridopidine (ACR16). Clinical Genetics—76(S1):74. (Abstract D10). [cited by applicant]
Xie, Yuxiang; Hayden, Michael R.; Xu, Baoji. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. Journal of Neuroscience, 2010, 30.44: 14708-14718. [cited by applicant]
Yung-Chi, Cheng; Prusoff, William H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical pharmacology, 197… [cited by applicant]
Zhan, L., et al. (2011). Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder. Neuropathology and applied neurobiology, 37(2), 206-219. [cited by applicant]
Zielonka, D. et al. (2015). Update on Huntington's disease: advances in care and emerging therapeutic options. Parkinsonism & related disorders, 21(3), 169-178. [cited by applicant]
Zuccato, Chiara, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 2001, 293.5529: 493-498. [cited by applicant]
Zuccato, Chiara; Cattaneo, Elena. Brain-derived neurotrophic factor in neurodegenerative diseases. Nature Reviews Neurology, 2009, 5.6: 311. [cited by applicant]
Zuccato, Chiara; Cattaneo, Elena. Role of brain-derived neurotrophic factor in Huntington's disease. Progress in neurobiology, 2007, 81.5-6: 294-330. [cited by applicant]
Reilmann, R., et al. (2024). Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Neurology, 23(3), 243-255. [cited by applicant]
Naoi, M., et al. (2022). Neuroprotective function of rasagiline and selegiline, inhibitors of type B monoamine oxidase, and role of monoamine oxidases in synucleinopathies. International Journal of Molecular Sciences, 2… [cited by applicant]
Nayak, L, & Henchcliffe, C. (2008). Rasagiline in treatment of Parkinson's disease. Neuropsychiatric Disease and Treatment, 4(1), 23-32. [cited by applicant]
Rascol, O., et al. (2005). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomise… [cited by applicant]